Eli Lilly and Company has emerged as in the production of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant potential to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide utilizes a series of carefully controlled procedur